Landmark prospective study reveals HER2DX® genomic test modified treatment decisions in 48.1% of early-stage HER2+ breast cancer cases, with 75.5% of changes resulting in reduced treatment intensity without compromising outcomes.

GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern.

Omada Health, a virtual care provider for chronic conditions like diabetes and hypertension, has filed for an IPO with Q1 2025 revenue of $55 million, representing a 57% year-over-year increase.

AC-201, an oral selective TYK2/JAK1 inhibitor, met its primary endpoint with up to 74.3% of patients achieving PASI-75 responses at week 12 across all three dosing regimens tested.

Eli Lilly's Mounjaro (tirzepatide) has shown superior efficacy in reducing HbA1c levels and body weight compared to Novo Nordisk's Ozempic in clinical trials, offering new hope for the 35 million Americans with type 2 diabetes.

The New England Journal of Medicine published data showing Takeda's investigational oral orexin receptor 2 agonist oveporexton demonstrated significant improvements in wakefulness and reduced cataplexy events in narcolepsy type 1 patients.

NHS England approves Casgevy, a gene-editing therapy, for treating severe sickle cell disease in eligible patients aged 12 and over.

Enveric Biosciences is progressing EB-003, a neuroplastogenic molecule, for treating mental health disorders without hallucinogenic effects.

Semaglutide, the active ingredient in Ozempic, demonstrates a 27% reduction in heart failure events among diabetes patients with chronic kidney disease.

A new study reveals that cannabidiol (CBD) significantly extends lifespan and alleviates symptoms in animal models of Leigh syndrome, a severe mitochondrial disease.

Roche remains confident in its obesity drug candidates despite initial concerns over side effects observed in a small study of CT-388, a weight-loss shot.

The Indian Council of Medical Research (ICMR) has signed agreements to advance first-in-human Phase 1 clinical trials for four molecules.

Adjuvant pembrolizumab plus chemotherapy did not improve disease-free survival (DFS) compared to chemotherapy alone in high-risk endometrial cancer patients.

In vitro studies indicate that ovarian carcinomas exhibit varied responses to cytostatic agents, with cyclophosphamide and trenimon demonstrating notable effectiveness.

Updated Phase 2 data on LUM-201 demonstrate sustained growth over 24 months in children with moderate Pediatric Growth Hormone Deficiency (PGHD).

Long-term data from Phase III open-label extension studies show Bylvay (odevixibat) provides sustained efficacy in treating Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome (ALGS).

Japan's MHLW has approved GSK's Arexvy vaccine for adults aged 50-59 at increased risk of RSV, expanding its previous authorization for those 60 and older.

Two-year data confirms bimekizumab's sustained clinical response in adults with active psoriatic arthritis and axial spondyloarthritis.

Ipsen presented data at AASLD 2024 showing Bylvay (odevixibat) provides sustained efficacy in treating Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome (ALGS).

Aurion Biotech's endothelial cell therapy demonstrates significant improvements in both best-corrected visual acuity and brightness acuity testing for corneal edema.